---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-097069"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2025-07-21T23:59:59+00:00"
generated_at: "2026-05-18T05:17:20.440665+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuvalent initiates Phase 3 ALKAZAR trial of neladalkib in ALK-positive NSCLC

## Summary
- First patient dosed in Phase 3 ALKAZAR trial evaluating neladalkib for TKI-naïve advanced ALK-positive NSCLC.
- Trial compares neladalkib head-to-head against ALECENSA (alectinib), a front-line standard of care.
- ALKAZAR is a registrational study designed to support potential approval of neladalkib in this indication.

## SEC filing metadata
- accession: 0000950170-25-097069
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2025-07-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017025097069/0000950170-25-097069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017025097069/nuvl-20250721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-097069
- JSON: https://secwatch.observer/filing/0000950170-25-097069.json
- Plain text: https://secwatch.observer/filing/0000950170-25-097069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.